Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1

Completed · Phase 1

Conditions studied: Myotonia Congenita, Paramyotonia Congenita, Myotonic Dystrophy 1

In brief

The purpose of this study is to gather preliminary data to determine if ranolazine is a safe and effective treatment for the symptoms of myotonia congenital, paramyotonia congenita, and myotonic dystrophy type 1. The duration of the study is 5 weeks.

Key facts

Study ID
NCT02251457
Run by
Ohio State University
People needed
35
Starts
2014-08-01
Expected to finish
2017-12-18
Last updated by the study team
2019-03-05

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.